These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

820 related items for PubMed ID: 9232251

  • 41. Treatment of relapsed and refractory Hodgkin's disease with high dose chemotherapy and autologous bone marrow transplantation.
    Brice P, Gisselbrecht C, Ferme C, Lepage E, Baruchel A, Marolleau JP, Gerota O, Boiron M.
    Nouv Rev Fr Hematol (1978); 1991; 33(3):267-72. PubMed ID: 1956765
    [Abstract] [Full Text] [Related]

  • 42. [Treatment outcomes and prognostic analyses of relapsed or refractory T-cell non-Hodgkin's lymphoma].
    Gao Y, Huang HQ, Lin XB, Cai QQ, Pan ZH, Wang BF, Bu Q.
    Ai Zheng; 2007 Aug; 26(8):909-13. PubMed ID: 17697558
    [Abstract] [Full Text] [Related]

  • 43. Early intensive therapy with autologous stem cell transplantation in advanced Hodgkin's disease: retrospective analysis of 158 cases from the French registry.
    Moreau P, Fleury J, Brice P, Colombat P, Bouabdallah R, Lioure B, Voillat L, Casasnovas O, François S, Sadoun A, Lamy T, Lotz JP, Munck JN, Divine M, Fermé C, Pény AM, Fruchart C, Oriol P, Ojeda M, Reman O, Milpied N, Gisselbrecht C, Legros M, Harousseau JL.
    Bone Marrow Transplant; 1998 Apr; 21(8):787-93. PubMed ID: 9603402
    [Abstract] [Full Text] [Related]

  • 44. Tandem transplant of peripheral blood stem cells for patients with poor-prognosis Hodgkins's disease or non-Hodgkin's lymphoma.
    Fitoussi O, Simon D, Brice P, Makke J, Scrobohaci ML, Bibi Triki T, Hennequin C, Fermé C, Gisselbrecht C.
    Bone Marrow Transplant; 1999 Oct; 24(7):747-55. PubMed ID: 10516678
    [Abstract] [Full Text] [Related]

  • 45. Busulfan, cyclophosphamide, and etoposide as high-dose conditioning regimen in patients with malignant lymphoma.
    Hänel M, Kröger N, Sonnenberg S, Bornhäuser M, Krüger W, Kroschinsky F, Hänel A, Metzner B, Birkmann J, Schmid B, Hoffknecht MM, Fiedler F, Ehninger G, Zander AR.
    Ann Hematol; 2002 Feb; 81(2):96-102. PubMed ID: 11907790
    [Abstract] [Full Text] [Related]

  • 46. Intensive conditioning regimen of etoposide (VP-16), cyclophosphamide and carmustine (VCB) followed by autologous hematopoietic stem cell transplantation for relapsed and refractory Hodgkin's lymphoma.
    Benekli M, Smiley SL, Younis T, Czuczman MS, Hernandez-Ilizaliturri F, Bambach B, Battiwalla M, Padmanabhan S, McCarthy PL, Hahn T.
    Bone Marrow Transplant; 2008 Apr; 41(7):613-9. PubMed ID: 18071290
    [Abstract] [Full Text] [Related]

  • 47. High-dose chemotherapy and autologous stem cell transplant in adolescent patients with relapsed or refractory Hodgkin's lymphoma.
    Akhtar S, El Weshi A, Rahal M, Abdelsalam M, Al Husseini H, Maghfoor I.
    Bone Marrow Transplant; 2010 Mar; 45(3):476-82. PubMed ID: 19734949
    [Abstract] [Full Text] [Related]

  • 48. BEAC or BEAM high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: comparative analysis of efficacy and toxicity.
    Jo JC, Kang BW, Jang G, Sym SJ, Lee SS, Koo JE, Kim JW, Kim S, Huh J, Suh C.
    Ann Hematol; 2008 Jan; 87(1):43-8. PubMed ID: 17710401
    [Abstract] [Full Text] [Related]

  • 49. High-dose chemotherapy with carboplatin, etoposide and ifosfamide followed by autologous stem cell rescue in patients with relapsed or refractory malignant lymphomas: a phase I/II study.
    Kleiner S, Kirsch A, Schwaner I, Kingreen D, Schwella N, Huhn D, Siegert W.
    Bone Marrow Transplant; 1997 Dec; 20(11):953-9. PubMed ID: 9422474
    [Abstract] [Full Text] [Related]

  • 50. High-dose ifosfamide in combination with etoposide and epirubicin (IVE) in the treatment of relapsed/refractory Hodgkin's disease and non-Hodgkin's lymphoma: a report on toxicity and efficacy.
    Proctor SJ, Taylor PR, Angus B, Wood K, Lennard AL, Lucraft H, Carey PJ, Stark A, Iqbal A, Haynes A, Russel N, Leonard RC, Culligan D, Conn J, Jackson GH.
    Eur J Haematol Suppl; 2001 Jul; 64():28-32. PubMed ID: 11486397
    [Abstract] [Full Text] [Related]

  • 51. Comparison of high-dose therapy and autologous stem-cell transplantation with conventional therapy for Hodgkin's disease induction failure: a case-control study. Société Francaise de Greffe de Moelle.
    André M, Henry-Amar M, Pico JL, Brice P, Blaise D, Kuentz M, Coiffier B, Colombat P, Cahn JY, Attal M, Fleury J, Milpied N, Nedellec G, Biron P, Tilly H, Jouet JP, Gisselbrecht C.
    J Clin Oncol; 1999 Jan; 17(1):222-9. PubMed ID: 10458237
    [Abstract] [Full Text] [Related]

  • 52. Single and double autotransplants for relapsing/refractory Hodgkin's disease: results of two consecutive trials.
    Ahmed T, Lake DE, Beer M, Feldman EJ, Preti RA, Seiter K, Helson L, Mittelman A, Kancherla R, Ascensao J, Akhtar T, Cook P, Goldberg R, Coleman M.
    Bone Marrow Transplant; 1997 Mar; 19(5):449-54. PubMed ID: 9052910
    [Abstract] [Full Text] [Related]

  • 53. High lactate dehydrogenase level is associated with an adverse outlook in autografting for Hodgkin's disease.
    Lumley MA, Milligan DW, Knechtli CJ, Long SG, Billingham LJ, McDonald DF.
    Bone Marrow Transplant; 1996 Mar; 17(3):383-8. PubMed ID: 8704691
    [Abstract] [Full Text] [Related]

  • 54. Peripheral blood stem cell transplantation for relapsed or refractory aggressive lymphoma in patients over 60 years of age.
    Stamatoullas A, Fruchart C, Khalfallah S, Buchonnet G, Contentin N, Bastit D, Tilly H.
    Bone Marrow Transplant; 1997 Jan; 19(1):31-5. PubMed ID: 9012928
    [Abstract] [Full Text] [Related]

  • 55. Outcome of children and adolescents with recurrent/refractory classical Hodgkin lymphoma, a study from the Société Française de Lutte contre le Cancer des Enfants et des Adolescents (SFCE).
    Gorde-Grosjean S, Oberlin O, Leblanc T, Pacquement H, Donadieu J, Lambilliotte A, Schell M, Dommange F, Munzer M, Paillard C, Schmitt C, Lutz P, Edan C, Ansoborlo S, Stephan JL, Michel G, Thomas C, Perel Y, Robert A, Landman-Parker J.
    Br J Haematol; 2012 Sep; 158(5):649-56. PubMed ID: 22757721
    [Abstract] [Full Text] [Related]

  • 56. [High dose therapy with autologous stem cell transplantation in patients with Hodgkin's lymphoma: long-term follow-up in patients treated in one center].
    Trnĕný M, Vacková B, Pytlík R, Cieslar P, Válková V, Gasová Z, Kobylka P, Trnková M, Krejcová H, Klener P.
    Cas Lek Cesk; 2006 Sep; 145(1):19-24. PubMed ID: 16468237
    [Abstract] [Full Text] [Related]

  • 57. Allogeneic bone marrow transplantation following a busulfan-based conditioning regimen in young children with acute lymphoblastic leukemia: a Cooperative Study of the Société Française de Greffe de Moelle.
    von Bueltzingsloewen A, Esperou-Bourdeau H, Souillet G, Demeocq F, Mechinaud-Lacroix F, Michel G, Sadoun A, Bernaudin F, Cornu G, Donadieu J.
    Bone Marrow Transplant; 1995 Oct; 16(4):521-7. PubMed ID: 8528167
    [Abstract] [Full Text] [Related]

  • 58. Long-term outcome of treatment for Hodgkin's disease: the University Hospital Sofia experience.
    Gocheva L, Koleva I.
    Klin Onkol; 2010 Oct; 23(1):34-42. PubMed ID: 20192072
    [Abstract] [Full Text] [Related]

  • 59. Comparison of autologous bone marrow transplantation and peripheral blood stem cell transplantation after first remission induction treatment in multiple myeloma.
    Harousseau JL, Attal M, Divine M, Milpied N, Marit G, Leblond V, Stoppa AM, Bourhis JH, Caillot D, Boasson M.
    Bone Marrow Transplant; 1995 Jun; 15(6):963-9. PubMed ID: 7581098
    [Abstract] [Full Text] [Related]

  • 60. Autologous stem cell transplantation after first remission induction treatment in multiple myeloma. A report of the French Registry on Autologous Transplantation in Multiple Myeloma.
    Harousseau JL, Attal M, Divine M, Marit G, Leblond V, Stoppa AM, Bourhis JH, Caillot D, Boasson M, Abgrall JF.
    Stem Cells; 1995 Aug; 13 Suppl 2():132-9. PubMed ID: 8520502
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 41.